10-Q: Journey Medical Corp Q3 2026: Revenue Up, Losses Persist

Journey Medical Corporation reported an 11% increase in net product revenue for the third quarter of 2026, driven by Emrosi sales, but continued to incur net losses, raising going concern doubts.

Summary

• Journey Medical Corporation reported total revenue of $18.97 million for the three months ended September 30, 2026, an increase of 8% from $17.63 million in the same period last year.
• Net product revenue grew 11% to $18.93 million, primarily due to a significant increase in Emrosi sales, which rose 84% to $9.00 million.
• However, the company reported a net loss of $1.32 million for the quarter, an improvement from a $2.32 million loss in the prior year's quarter.
• For the nine months ended September 30, 2026, total revenue increased 17% to $53.44 million, with net product revenue up 17% to $52.69 million.
• The net loss for the nine-month period narrowed to $3.86 million from $10.18 million in the prior year.
• Despite revenue growth, the company continues to face challenges, with substantial doubt existing about its ability to continue as a going concern.
• Cash and cash equivalents decreased to $22.32 million as of September 30, 2026, from $24.09 million at December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to continued net losses and substantial doubt about the company's ability to continue as a going concern, despite revenue growth.

Positives

• Total revenue increased by 8% to $18.97 million for the three-month period ended September 30, 2026.
• Net product revenue increased by 11% to $18.93 million for the three-month period ended September 30, 2026.
• Emrosi sales showed strong growth, increasing by 84% to $9.00 million in the third quarter of 2026.
• Net loss for the three-month period improved to $1.32 million, a 43% reduction compared to $2.32 million in the prior year.
• Total revenue for the nine-month period increased by 17% to $53.44 million.
• Net product revenue for the nine-month period increased by 17% to $52.69 million.
• Net loss for the nine-month period significantly narrowed to $3.86 million from $10.18 million in the prior year.

Negatives

• The company reported a net loss of $1.32 million for the three-month period ended September 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Cash and cash equivalents decreased to $22.32 million as of September 30, 2026, from $24.09 million at December 31, 2025.
• Working capital decreased to $25.7 million from $29.4 million.
• Other revenue decreased by 93% to $0.04 million due to the cessation of Cutia supply agreement revenue.
• Qbrexza sales decreased by 24% to $5.59 million in the third quarter of 2026.
• Foam franchise products (Amzeeq & Zilxi) sales decreased by 28% to $0.94 million in the third quarter of 2026.
• A $1.7 million incremental expense was recognized due to the settlement of a vendor dispute.

Risks

• Products are subject to time and cost-intensive regulation and clinical testing, and may never be successfully developed or commercialized.
• A substantial portion of sales derive from products that may become subject to third-party generic competition.
• The company operates in a heavily regulated industry, and future legislation or administrative actions could impact operations.
• Revenue is dependent mainly upon sales of dermatology products, and any setback could impair operating results.
• Competition could limit product commercial opportunity and profitability, including from generic versions.
• Products may not achieve broad market acceptance, including by government and third-party payors.
• Reliance on third parties for several aspects of operations.
• Dependence on the ability to identify, develop, acquire, or in-license products and integrate them successfully.

Future Outlook

The company regularly evaluates market conditions, its liquidity profile, and financing alternatives to enhance its capital structure. It may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives. However, substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the issuance date of these financial statements.

Management Comments

• The company is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions.
• The company's current product portfolio includes nine FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S.
• We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market.
• We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization.
• We are a controlled subsidiary of Fortress.

Industry Context

StockSavvy.ai notes that Journey Medical operates in the competitive dermatology pharmaceutical market. The reported revenue growth, particularly from Emrosi, is positive, but the persistent net losses and going concern doubts highlight the financial pressures common in the industry, especially for companies reliant on a few key products and facing generic competition.

Comparison to Industry Standards

• The company's revenue growth of 11% year-over-year for the quarter is solid, but the pharmaceutical industry average can vary significantly based on product lifecycle and market segment. Companies with successful new drug launches often see higher growth rates.
• The net loss, while reduced, indicates that the company is not yet profitable. Many pharmaceutical companies, especially those in the commercialization phase or with significant R&D pipelines, experience periods of net loss. However, sustained losses raise concerns about long-term viability.
• The significant increase in gross-to-net sales accruals, particularly for Emrosi coupons, suggests aggressive sales strategies to drive volume, which is a common practice but can impact net revenue realization.
• The company's reliance on a few key products (Emrosi, Qbrexza) makes it vulnerable to market shifts and competition, a risk factor present across the pharmaceutical sector.

Legal Proceedings

• To the company's knowledge, there are no legal proceedings pending against it, other than routine actions, administrative proceedings, and other actions not deemed material, that are expected to have a material adverse effect on its financial condition, results of operations, or cash flows.
• In the ordinary course of business, the Company may be subject to both insured and uninsured litigation, including suits and claims by customers, suppliers, partners, and/or third parties.

Related Party Transactions

• The Company has a Shared Services Agreement with Fortress Biotech, Inc. (Fortress) to share the cost of certain employees. Fortress's Executive Chairman and Chief Executive Officer is also the Executive Chairman of Journey Medical.
• Journey Medical reimburses Fortress for salary and benefit costs of shared employees based on hours worked.
• Journey Medical also reimburses Fortress for various payroll-related costs and SG&A costs incurred by Fortress for the Company's benefit.
• Related party expenses to Fortress were approximately $10,000 for the three-month period and $35,000 for the nine-month period ended September 30, 2026.
• Due to related party liability was $0.8 million at September 30, 2026, primarily related to reimbursable expenses incurred by Fortress.

Stakeholder Impact

• Shareholders: Continued net losses and going concern doubts may negatively impact share price and investor confidence. Potential capital raises could dilute existing shareholders.
• Creditors: The company's ability to meet its debt obligations, including the SWK Credit Facility, is a key concern given the going concern doubt.
• Employees: Uncertainty regarding the company's future could impact employee morale and retention.
• Suppliers: The company's financial health could affect its ability to meet payment obligations to suppliers.
• Customers: Continued product availability and potential future product development are important for customers.

Next Steps

• Continue to fund core operations through cash on hand generated from sales.
• Utilize proceeds from the term loan Credit Facility and at-the-market sales program for capital and liquidity needs.
• Regularly evaluate market conditions, liquidity profile, and financing alternatives.
• Potentially seek capital through debt or equity financings.
• Continue commercialization efforts for existing products, including Emrosi.
• Monitor compliance with financial covenants under the SWK Credit Facility.

Key Dates

Recommendation

The company shows revenue growth and narrowing losses, which are positive signs. However, the persistent net losses, substantial doubt about its ability to continue as a going concern, and the need for potential future capital raises present significant risks. While there's potential for recovery if Emrosi continues to perform and the company manages its finances, the current situation warrants a cautious 'hold' stance until profitability and financial stability are more clearly demonstrated.

Keywords

dermatology, pharmaceutical, Emrosi, Qbrexza, Amzeeq, Zilxi, Accutane, revenue growth